Interviews on biotechnology

Interview 9 Oct 2017

The Woman Developing the Next Generation of Cancer Immunotherapy

Özlem Türeci discusses the future of individualized cancer therapy and her journey to become an entrepreneur and take science to patients. As a trained physician and immunologist, Dr. Özlem Türeci has led her own research group with Prof. Ugur Sahin at the University of Mainz, Germany, since 2000. But academic research was not enough for her, […]

October 9, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

ulf grawunder nbe therapeutics interview

Interview 4 Oct 2017

4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology

ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what NBE is doing differently from its predecessors. Ever since the first antibody-drug conjugate (ADC) was approved in 2001, there has been a lot of excitement about the technology. “Some people even referred to ADCs as a ‘magic bullet,’” recalls Ulf […]

October 4, 2017 - 5 minutesmins - By Evelyn Warner

Interview 28 Sep 2017

What are Alphabodies and How Do They Drug the Undruggable?

Philip found out more about a new form of protein therapeutics being developed by Complix, which aims to drug the undruggable. Mark Vaeck, Co-Founder and CEO of Complix, has over 25 years experience in the biotech and pharma industries. His latest company Complix, a Belgian immuno-oncology biotech, is developing Alphabodies, tiny therapeutic proteins that can […]

September 28, 2017 - 3 minutesmins - By Alex Dale

Interview 28 Sep 2017

Ethical Drug Development can Start with Charity Investors: A Conversation

As the furor over drug pricing has driven the biopharma industry to reflect on its ethics, I sat down with David Pardoe of LifeArc to discuss the involvement of charity investors. In August, a story emerged that Novartis CEO Joe Jimenez not only responded to a patient’s letter but met with him soon thereafter to […]

September 28, 2017 - 6 minutesmins - By Evelyn Warner

Interview 27 Sep 2017

What’s this Top Swiss VC Up To These Days? General Partner Tells All

Philip caught up with Markus Hosang to find out which companies the VC is keeping an eye on after its next round of fundraising. General Partner, Markus Hosang has a strong background in pharma and VC, which serves him well when searching through the bustling biotech industry in Europe. BioMed Partners is a very active […]

September 27, 2017 - 3 minutesmins - By Alex Dale

Interview 25 Sep 2017

Meet the Founder & CEO of Galapagos, Europe’s Biotech Role Model

Onno van de Stolpe founded Galapagos nearly 20 years ago and still is CEO of this European biotech success story. I caught up with him for the full story. It was when he was studying at the agricultural university in Wageningen, The Netherlands, when “I got fascinated by molecular biology, and the biotech industry in […]

September 25, 2017 - 10 minutesmins - By Evelyn Warner

derek jones babraham bioscience technologies incubator

Interview 20 Sep 2017

A Peek Inside Europe’s Best Incubator: A Conversation with Babraham’s Chief Executive

Derek Jones is at the helm of Babraham Bioscience Technologies. I caught up with him to talk about strategies for biotech startups. Confusion is common when it comes to navigating the various organizing entities of Babraham, a life science campus just a few kilometers southeast of Cambridge. It’s famously home to a number of standout […]

September 20, 2017 - 9 minutesmins - By Evelyn Warner

David Chiswell interview Kymab Antibodies

Interview 18 Sep 2017

David Chiswell: “We are getting close to the best way of making antibodies”

We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he has the ambition to turn into the “European Genentech.” David Chiswell was, along with Greg Winter, one of the co-founders of Cambridge Antibody Technology. “We both wanted to start an antibody company,” says Chiswell. “And […]

September 18, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Interview 14 Sep 2017

Inside the Lab Building a Stem Cell Gun to Heal Skin

Thomas Bold, CEO of RenovaCare, shares the story of how his team developed a futuristic stem cell gun to heal burns and wounds. Inside the building that used to be home to Berlin’s Tempelhof airport, whose abandoned runways are regularly visited by picnickers and skaters, an American and a German company are collaborating on the […]

September 14, 2017 - 6 minutesmins - By Clara Rodríguez Fernández

Interview 11 Sep 2017

Meet the CEO of Europe’s Largest & Most Fiercely Independent Biotech

Jan van de Winkel co-founded Genmab as CSO and then became CEO to develop the antibody company into a fully independent commercial enterprise. Here’s his strategy. Since its foundation in 1999, Genmab has become Europe’s largest biotech and a proud parent of a half billion-euro drug, daratumumab. Co-founding CSO Jan van de Winkel played a […]

September 11, 2017 - 8 minutesmins - By Evelyn Warner

Interview 6 Sep 2017

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech vying for a piece of the pie. Though he spent 20 years in investment […]

September 6, 2017 - 6 minutesmins - By Evelyn Warner

Interview 4 Sep 2017

Meet this Blockbuster Developer turned Partner at a Headlining VC

Kevin Johnson told me the story and lessons of his career, from CTO of Cambridge Antibody Technology to General Partner at Medicxi. Since starting his biotech career as the lead developer of one of biotech’s biggest success stories, Humira, Kevin Johnson has continued in biotech as a force to be reckoned with. He joined the […]

September 4, 2017 - 7 minutesmins - By Evelyn Warner

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us